Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts $4.85 -0.07 (-1.42%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Karyopharm Therapeutics Earnings Summary Karyopharm Therapeutics released Q1 2025 earnings on May 12, 2025, reporting an EPS of -$2.77, which beat the consensus estimate of -$4.21 by $1.44. Quarterly revenue was reported to be $30.02 million, below analysts' expectations of $35.12 million. With a trailing EPS of -$15.29, Karyopharm Therapeutics' earnings are expected to grow next year, from ($0.71) to ($0.43) per share. Latest Q1 Earnings DateMay. 12EstimatedConsensus EPS (May. 12) -$4.21 Actual EPS (May. 12) -$2.77 Beat By $1.44 Actual Revenue (May. 12) $30.02MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Karyopharm Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Karyopharm Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKPTI Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KPTI Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Karyopharm Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20252-$4.37-$0.26-$2.32Q2 20252-$4.19-$0.25-$2.22Q3 20252-$3.39-$0.15-$1.77Q4 20252-$3.81-$0.15-$1.98 Karyopharm Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025-$4.21-$2.77+$1.44-$2.77$35.12M$30.02M2/19/2025Q4 2024-$3.90-$3.60+$0.30-$0.24$30.29M$30.54M11/5/2024Q3 2024-$4.05-$3.90+$0.15-$0.26$37.86M$38.78M8/6/2024Q2 2024-$4.35-$3.00+$1.35-$0.20$36.07M$42.79M5/8/2024Q1 2024-$4.95-$4.80+$0.15-$0.32$35.02M$33.13M2/29/2024Q4 2023-$4.35-$5.40 -$1.05-$0.36$33.50M$33.75M11/2/2023Q3 2023-$4.20-$4.50 -$0.30-$0.30$37.34M$36.01M8/2/2023Q2 2023-$5.10-$4.35+$0.75-$0.29$36.23M$37.58M Karyopharm Therapeutics Earnings - Frequently Asked Questions When did Karyopharm Therapeutics announce their last quarterly earnings? Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earning data on Monday, May 12, 2025. Learn more on KPTI's earnings history. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics issued an update on its FY 2025 earnings guidance on Monday, May, 12th. The company issued revenue guidance of $140.0 million-$155.0 million, compared to the consensus revenue estimate of $149.6 million. Did Karyopharm Therapeutics beat their earnings estimates last quarter? In the previous quarter, Karyopharm Therapeutics (NASDAQ:KPTI) reported ($2.77) earnings per share (EPS) to beat the analysts' consensus estimate of ($4.21) by $1.44. Learn more on analysts' earnings estimate vs. KPTI's actual earnings. How can I listen to Karyopharm Therapeutics's earnings conference call? The conference call for Karyopharm Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Karyopharm Therapeutics's conference call transcript? The conference call transcript for Karyopharm Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Karyopharm Therapeutics generate each year? Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded annual revenue of $145.24 million. How much profit does Karyopharm Therapeutics generate each year? Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded net income of -$143.10 million. KPTI has generated -$15.29 earnings per share over the last four quarters. What is Karyopharm Therapeutics's EPS forecast for next year? Karyopharm Therapeutics's earnings are expected to grow from ($0.71) per share to ($0.43) per share in the next year. More Earnings Resources from MarketBeat Related Companies DSGN Earnings Date HUMA Earnings Date OCGN Earnings Date ACTU Earnings Date MDWD Earnings Date NVCT Earnings Date ANNX Earnings Date CRGX Earnings Date VYGR Earnings Date YMAB Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? This page (NASDAQ:KPTI) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredCan This System Really Predict Stocks to the Day?Imagine foreseeing a 30% stock jump — to the day — weeks before it happens. Introducing a new way to predict t...InvestorPlace | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPTI Stock Free KPTI Stock Alerts